Niaspan treatment induces neuroprotection after stroke

Neurobiology of Disease

Volumn 40, Issue 1, 2010, Pages 277-283

  Shehadah, Amjad ^a   Chen, Jieli ^a   Zacharek, Alex ^a   Cui, Yisheng ^a   Ion, Madalina ^a   Roberts, Cynthia ^a   Kapke, Alissa ^a   Chopp, Michael ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

Apoptosis; Cleaved caspase 3; Neuroprotection; Niaspan; PI3K Akt; TNF alpha; VEGF

Indexed keywords

CASPASE 3; DNA NUCLEOTIDYLEXOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FUNCTIONAL ASSESSMENT; IMMUNOHISTOCHEMISTRY; MALE; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NICK END LABELING; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ANIMALS; BRAIN INFARCTION; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; NEUROPROTECTIVE AGENTS; NIACIN; RATS; RATS, WISTAR; STROKE; VITAMIN B COMPLEX;

EID: 77955846486     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.05.034     Document Type: Article

References (60)

1. Barone F.C., et al. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 1997, 28:1233-1244.
2. Barth T.M., et al. Effects of MK-801 on recovery from sensorimotor cortex lesions. Stroke 1990, 21:153-157. III.
3. Becker K.J. Inflammation and acute stroke. Curr. Opin. Neurol. 1998, 11:45-49.
4. Calza L., et al. Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors. Proc. Nat. Acad. Sci. U.S.A. 2001, 98:4160-4165.
5. Carlson L.A. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int. J. Clin. Pract. 2004, 58:706-713.
6. Chen C.F., et al. The protective effect of niacinamide on ischemia-reperfusion-induced liver injury. J. Biomed. Sci. 2001, 8:446-452.
7. Chen J., et al. Niaspan treatment increases tumor necrosis factor-alpha-converting enzyme and promotes arteriogenesis after stroke. J. Cereb. Blood Flow Metab. 2009, 29:911-920.
8. Chen J., et al. Niaspan increases angiogenesis and improves functional recovery after stroke. Ann. Neurol. 2007, 62:49-58.
9. Chen J., et al. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J. Neurol. Sci. 2001, 189:49-57.
10. Chen J., et al. Vascular endothelial growth factor mediates atorvastatin-induced mammalian achaete-scute homologue-1 gene expression and neuronal differentiation after stroke in retired breeder rats. Neuroscience 2006, 141:737-744.
11. Chen J., et al. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ. Res. 2003, 92:692-699.
12. Chen J., et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann. Neurol. 2003, 53:743-751.
13. Chong Z.Z., et al. Nicotinamide modulates mitochondrial membrane potential and cysteine protease activity during cerebral vascular endothelial cell injury. J. Vasc. Res. 2002, 39:131-147.
14. Chong Z.Z., et al. The NAD+precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. J. Cereb. Blood Flow Metab. 2004, 24:728-743.
15. DeGraba T.J. The role of inflammation after acute stroke: utility of pursuing anti-adhesion molecule therapy. Neurology 1998, 51:S62-S68.
16. Elam M.B., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000, 284:1263-1270.
17. Fukuzawa M., et al. Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-alpha. Immunol. Lett. 1997, 59:7-11.
18. Ganji S.H., et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009, 202:68-75.
19. Graham S.H., Chen J. Programmed cell death in cerebral ischemia. J. Cereb. Blood Flow Metab. 2001, 21:99-109.
20. Hallenbeck J.M. The many faces of tumor necrosis factor in stroke. Nat. Med. 2002, 8:1363-1368.
21. Hosomi N., et al. Tumor necrosis factor-alpha neutralization reduced cerebral edema through inhibition of matrix metalloproteinase production after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 2005, 25:959-967.
22. Hsu H., et al. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996, 84:299-308.
23. Jin K.L., et al. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc. Nat. Acad. Sci. U.S.A. 2000, 97:10242-10247.
24. Keck P.J., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989, 246:1309-1312.
25. Kilic E., et al. The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J. 2006, 20:1185-1187.
26. Kirino T. Delayed neuronal death. Neuropathology 2000, 20(Suppl):S95-S97.
27. Kuvin J.T., et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am. J. Cardiol. 2006, 98:743-745.
28. Le D.A., et al. Caspase activation and neuroprotection in caspase-3- deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc. Nat. Acad. Sci. U.S.A. 2002, 99:15188-15193.
29. Leung D.W., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
30. Li F., et al. Cell Life versus cell longevity: the mysteries surrounding the NAD+precursor nicotinamide. Curr. Med. Chem. 2006, 13:883-895.
31. Li, Y., et al., 1998. Neuronal damage and plasticity identified by microtubule-associated protein 2, growth-associated protein 43, and cyclin D1 immunoreactivity after focal cerebral ischemia in rats. Stroke. 29, 1972-80; discussion 1980-1.
32. Lin S.H., et al. Prevention of nitric oxide-induced neuronal injury through the modulation of independent pathways of programmed cell death. J. Cereb. Blood Flow Metab. 2000, 20:1380-1391.
33. Lu M., et al. Global test statistics for treatment effect of stroke and traumatic brain injury in rats with administration of bone marrow stromal cells. J. Neurosci. Meth. 2003, 128:183-190.
34. Lunn J.S., et al. Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration. Dev. Neurobiol. 2009, 69:871-884.
35. Luo Y., et al. Induction of caspase-activated deoxyribonuclease activity after focal cerebral ischemia and reperfusion. J. Cereb. Blood Flow Metab. 2002, 22:15-20.
36. Maiese K., Chong Z.Z. Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol. Sci. 2003, 24:228-232.
37. Manabat C., et al. Reperfusion differentially induces caspase-3 activation in ischemic core and penumbra after stroke in immature brain. Stroke 2003, 34:207-213.
38. Meyers C.D., et al. Niacin therapy in atherosclerosis. Curr. Opin. Lipidol. 2004, 15:659-665.
39. Mokudai T., et al. Delayed treatment with nicotinamide (Vitamin B(3)) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats. Stroke 2000, 31:1679-1685.
40. Morales J.R., et al. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Circulation 2008, 118:1450-1459.
41. Namura S., et al. Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. J. Neurosci. 1998, 18:3659-3668.
42. Nawashiro H., et al. Inhibition of tumor necrosis factor and amelioration of brain infarction in mice. J. Cereb. Blood Flow Metab. 1997, 17:229-232.
43. Osaki M., et al. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
44. Rabuffetti M., et al. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J. Neurosci. 2000, 20:4398-4404.
45. Schallert T., et al. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
46. Schulz J.B., et al. Caspases as treatment targets in stroke and neurodegenerative diseases. Ann. Neurol. 1999, 45:421-429.
47. Sehara Y., et al. Decreased focal inflammatory response by G-CSF may improve stroke outcome after transient middle cerebral artery occlusion in rats. J. Neurosci. Res. 2007, 85:2167-2174.
48. Shohami E., et al. Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev. 1999, 10:119-130.
49. Storkebaum E., et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 2005, 8:85-92.
50. Sun F.Y., Guo X. Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor. J. Neurosci. Res. 2005, 79:180-184.
51. Sun Y., et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest. 2003, 111:1843-1851.
52. Suzuki S., et al. Ambivalent aspects of interleukin-6 in cerebral ischemia: inflammatory versus neurotrophic aspects. J. Cereb. Blood Flow Metab. 2009, 29:464-479.
53. Swanson R.A., et al. A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 1990, 10:290-293.
54. Ungerstedt J.S., et al. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin. Exp. Immunol. 2003, 131:48-52.
55. Wang X., et al. Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol. Pharmacol. 2004, 65:890-896.
56. Wu, B. J., et al., 2010. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 30 (5), 968-975.
57. Yang J., et al. Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model. Pharmacol. Biochem. Behav. 2002, 73:901-910.
58. Yang Z.J., et al. Role of vascular endothelial growth factor in neuronal DNA damage and repair in rat brain following a transient cerebral ischemia. J. Neurosci. Res. 2002, 70:140-149.
59. Yin W., et al. Preconditioning suppresses inflammation in neonatal hypoxic ischemia via Akt activation. Stroke 2007, 38:1017-1024.
60. Zhang Z.G., et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Invest. 2000, 106:829-838.